Funding for this research was provided by:
Health Technology Assessment Programme (14/158/02)
NIHR School for Primary Care Research
The UK Medical Research Council and Wellcome (102215/2/13/2)
Received: 19 March 2020
Accepted: 26 August 2020
First Online: 2 November 2020
Ethics approval and consent to participate
: Not applicable. The study involved secondary analysis of existing anonymised data.
: Not applicable
: The authors disclose support from NIHR HTA for the submitted work. LCC reports being Chair of the HTA CET Committee from January 2019. AK reports being a member of the NIHR HTA board. BWM reports grants from Merck; personal fees from OvsEva, Merck, and Guerbet; and other from NHMRC, Guerbet, and Merch, outside the submitted work. GS reports grants and personal fees from GlaxoSmithKline Research and Development Limited, grants from Sera Prognostics Inc., non-financial support from Illumina Inc., and personal fees and non-financial support from Roche Diagnostics Ltd., outside the submitted work. JK reports personal fees from Roche Canada, outside the submitted work. JM reports grants from National Health Research and Development Program, Health and Welfare Canada, during the conduct of the study. JEN reports grants from Chief Scientist Office Scotland, other from GlaxoSmithKline and Dilafor, outside the submitted work. AG reports personal fees from Roche Diagnostics, outside the submitted work. IH reports personal fees from Roche Diagnostics and Thermo Fisher, outside the submitted work. RR reports personal fees from the BMJ, Roche, and Universities of Leeds, Edinburgh, and Exeter, outside the submitted work.